Man­u­fac­tur­ing roundup: Au­risco com­pletes FDA in­spec­tion of in­gre­di­ent pro­duc­tion site; NIH picks Exothera to de­vel­op nasal Covid vac­cine

Au­risco Phar­ma­ceu­ti­cal said Tues­day that the FDA gave it the green light to pro­duce ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (APIs) at a man­u­fac­tur­ing site in Yangzhou, Chi­na …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER